• Archives of Pharmacal Research
• /
• 제13권2호
• /
• pp.180-186
• /
• 1990

A bioequivalence study of ranitidine tablets was conducted according to the Korean Guidine for the Bioequivalence Test using twelve healthy male subjects. The plasma concentration-timecurves of ranitidine from the test and reference tablets showed profound multiple peak phenomenon in each subject as reported earlier. However, the area under the plasma concentration-time curve (AUC) and the maximum ploasma concentration at the first peak ($C_{max1}$) of the two preparations was proven to be equal when analyzed satistically according to the criteria of the guidline;i. e., statistical power (1-$\beta$)was calculated to be over 0.8 under the condition of $\alpha$ = 5% and $\Delta$(minimum detectable difference) = 20%, and the confidence interval of the difference in AUC at 95% confidence level was in the range of $\pm$ 20%, which statisfied the criteria of bioequivalence. Equivalence of the peak concentration of ranitidine at the second peak ($C_{max2}$), and the time to reach the first ($T_{max1}$) and second verify the bioequivalence of $c_{max2}$ , $T_{max1}$ and $T_{max2}$ between the two tablets. However, we conclude that the test and reference tablets are bioequivalent taking the therapeutic characteristics of the ranitidine preparations into consideration.

• Journal of Pharmaceutical Investigation
• /
• 제36권3호
• /
• pp.193-199
• /
• 2006

A bioequivalence study of $Sudo^{TM}$ Ranitidine HCI tablet (Sudo Pharma. Ind. Co., Ltd.) to $Curan^{TM}$ tablet (Il Dong Pharma. Ind. Co., Ltd.) was conducted according to the guidelines of Korea Food and Drug Administration (KFDA). Twenty four healthy male Korean volunteers received each medicine at the ranitidine hydrochloride dose of 150 mg in a 2x2 crossover study. There was a one week wash-out period between the doses. Plasma concentrations of ranitidine were monitored by a high-turbulent liquid chromatography (HTLC) for over a period of 12 hours after drug administration. $AUC_t$ (the area under the plasma concentration-time curve from time zero to 12 hr) was calculated by the linear trapezoidal rule method. $C_{max}$ (maximum plasma drug concentration) and $T_{max}$ (time to reach $C_{max}$) were compiled from the plasma concentration-time data. Analysis of variance was carried out using logarithmically transformed $AUC_t$ and $C_{max}$. No significant sequence effect was found far all of the bioavailability parameters indicating that the crossover design was properly performed. The 90% confidence intervals of the $AUC_t$ ratio and the $C_{max}$ ratio for $Sudo^{TM}$ Ranitidine $HCl/Curan^{TM}$ were 0.92-1.00 and 0.90-1.03, respectively. These values were within the acceptable bioequivalence intervals of 0.80-1.25. Thus, our study demonstrated the bioequivalence of $Sudo^{TM}$ Ranitidine HCI and $Curan^{TM}$ with respect to the rate and extent of absorption.

• 분석과학
• /
• 제22권5호
• /
• pp.432-438
• /
• 2009

Ranitidine HCl을 함유하는 의약품 정제에 대한 네모파 전압전류법(SWV) 분석방법을 개발하고자 다양한 pH의 인산염 완충용액을 지지전해질로 하여 $5.00{\times}10^{-5}M$ ranitidine HCl용액의 SWV를 실행한 결과 ranitidine의 구조 내 $-NO_2$기의 전기화학적 환원에 기인한 주 봉우리는 Ep가 -70 mV/pH로 이동하여 수소가 관여함을 나타내었다. Ranitidine HCl용액 $1.00{\times}10^{-7}{\sim}1.00{\times}10^{-5}M$에 대하여 봉우리 전류(Ip)를 도시하여 검량곡선을 작성 시 좋은 직선성을 나타내었으며 기울기는 $232,530{\mu}A/M$ (pH 6.14), $289,015{\mu}A/M$ (pH 7.07)과 $232,843{\mu}A/M$ (pH 8.01)이었다. 의약품 정제 1정을 단순히 pH 6.14 인산염 완충용액에 용해시켜 표준물 첨가법에 의해 SWV로 정량분석 할 때 하루 중 정밀도 검사(n=4)는 큐란$^{(R)}$의 경우 1정 중 $171{\pm}2.1mg$(규정된 함량의 $102{\pm}1.3%$)의 ranitidine HCl이 함유되어 1.2% RSD를 보였으며, 5일에 걸쳐 날짜 간 정밀도 검사를 행하였을 때에도 1.1%의 RSD를 나타내었다. 잔탁$^{(R)}$ 역시 하루 중 정밀도 검사(n=4)를 하였을 때 1정 중 $167{\pm}0.8mg$(규정된 함량의 $99{\pm}0.5%$)의 ranitidine HCl이 함유되어 0.5%의 RSD를, 날짜 간 정밀도 검사도 0.3%의 RSD로 좋은 정밀도를 나타내었다.